The Wnt signaling pathway: Implications for therapy in osteosarcoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1223-1232

  McQueen, Peter ^a   Ghaffar, Samia ^a   Guo, Yi ^a   Rubin, Elyssa M ^b   Zi, Xiaolin ^c   Hoang, Bang H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

c Met; cancer stem cells; DKK3; Frzb; LRP5; osteosarcoma; WIF 1; Wnt signaling

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; BETA CATENIN; BEVACIZUMAB; CALCITRIOL; CURCUMIN; DICKKOPF 3 PROTEIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; FRIZZLED PROTEIN; GEFITINIB; IMATINIB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; NONSTEROID ANTIINFLAMMATORY AGENT; PF 2362376; PIPERINE; PNU 74654; POLYPHENOL; PROTEIN FRP3; PROTEIN FZD10; PROTEIN INHIBITOR; QUERCETIN; RECOMBINANT PROTEIN; RESVERATROL; RETINOL; STA 1474; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVITY; COLON CANCER; DRUG MECHANISM; DRUG TARGETING; EVENT FREE SURVIVAL; GENE TARGETING; HUMAN; LUNG METASTASIS; METASTASIS POTENTIAL; NONHUMAN; ORTHOPEDIC SURGERY; OSSIFICATION; OSTEOSARCOMA; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SARCOMA CELL; SIGNAL TRANSDUCTION; SURVIVAL TIME; TARGET CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; OSTEOSARCOMA; WNT SIGNALING PATHWAY;

EID: 80052324818     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.94     Document Type: Review

References (80)

1. Hayden JB, Hoang BH. Osteosarcoma: Basic science and clinical implications. Orthop. Clin. North. Am. 37(1), 1-7 (2006).
2. Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314(25), 1600-1606 (1986).
3. Cleton-Jansen A-M, Anninga JK, Briaire-De Bruijn IH et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br. J. Cancer 101(11), 1909-1918 (2009).
4. Moon RT. Wnt/b-catenin pathway. Sci. STKE 2005(271), (2005).
5. Paul S, Dey A. Wnt signaling and cancer development: Therapeutic implication. Neoplasma 55(3), 165-176 (2008).
6. Luo J, Chen J, Deng Z-L et al. Wnt signaling and human diseases: What are the therapeutic implications? Lab. Invest 87(2), 97-103 (2007).
7. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug. Discov. 5(12), 997-1014 (2006).
8. Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4), 513-523 (2001).
9. Kato M, Patel MS, Levasseur R et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157(2), 303-314 (2002).
10. Babij P, Zhao W, Small C et al. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner Res. 18(6), 960-974 (2003).
11. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr. Opin. Rheumatol. 19(4), 376-382 (2007).
12. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116(5), 1202-1209 (2006).
13. Haydon RC, Deyrup A, Ishikawa A et al. Cytoplasmic and/or nuclear accumulation of the b-catenin protein is a frequent event in human osteosarcoma. Int. J. Cancer 102(4), 338-342 (2002).
14. Enomoto M, Hayakawa S, Itsukushima S et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28(36), 3197-3208 (2009).
15. Hoang BH, Kubo T, Healey JH et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int. J. Cancer 109(1), 106-111 (2004). Shows that aberrant activation of Wnt signaling in osteosarcoma is associated with worse prognosis.
16. Mandal D, Srivastava A, Mahlum E et al. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 386(1-2), 131-138 (2007). Demonstrates that Wnt inhibitor Frzb/sFRP3 exhibits decreased expression in osteosarcoma samples.
17. Kansara M, Tsang M, Kodjabachian L et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119(4), 837-851 (2009).
18. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/b-catenin pathway in conventional high-grade osteosarcoma. J. Pathol. 220(1), 24-33 (2010).
19. Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest.117(11), 3248-3257 (2007).
20. Lin YC, You L, Xu Z et al. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem. Biophys. Res. Commun. 341(2), 635-640 (2006).
21. Mazieres J, He B, You L et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64(14), 4717-4720 (2004).
22. Batra S, Shi Y, Kuchenbecker KM et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys. Res. Commun. 342(4), 1228-1232 (2006).
23. Ai L, Tao Q, Zhong S et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27(7), 1341-1348 (2006).
24. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 97(1), 64-71 (2006).
25. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 9(3), 731-741 (2010).
26. Guo Y, Xie J, Rubin E et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 68(9), 3350-3360 (2008).
27. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. The soluble Wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 67(11), 5371-5379 (2007). Verified the therapeutic potential for Wnt pathway inhibitors.
28. Monaghan H, Bubb VJ, Sirimujalin R, Millward-Sadler SJ, Salter DM. Adenomatous polyposis coli (APC), b-catenin, and cadherin are expressed in human bone and cartilage. Histopathology 39(6), 611-619 (2001).
29. Hoang BH, Kubo T, Healey JH et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-b-catenin pathway. Cancer Res. 64(8), 2734-2739 (2004).
30. Fedi P, Bafico A, Nieto Soria A et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 274(27), 19465-19472 (1999).
31. Guo Y, Zi X, Koontz Z et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J. Orthop. Res. 25(7), 964-971 (2007).
32. Guo Y, Rubin EM, Xie J, Zi X, Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin. Orthop. Relat. Res. 466(9), 2039-2045 (2008). Verified the therapeutic signifiance of Wnt inhibitors in osteosarcoma.
33. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development (Cambridge, England) 136(19), 3205-3214 (2009).
34. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits b-catenin-TCF signaling depending on receptor context. PLoS Biol. 4(4), e115 (2006).
35. Oishi I, Suzuki H, Onishi N et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8(7), 645-654 (2003).
36. Morioka K, Tanikawa C, Ochi K et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 100(7), 1227-1233 (2009).
37. Nagayama S, Katagiri T, Tsunoda T et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 62(20), 5859-5866 (2002).
38. Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 24(41), 6201-6212 (2005).
39. Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y, Katagiri T. Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene 28(8), 1110-1120 (2009).
40. Coltella N, Manara MC, Cerisano V et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 17(9), 1162-1164 (2003).
41. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 62(18), 5126-5128 (2002).
42. Patané S, Avnet S, Coltella N et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66(9), 4750-4757 (2006).
43. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs 23(5), 391-409 (2005).
44. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology, 69(Suppl. 3), 46-56 (2005).
45. Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets 6(3), 259-274 (2005).
46. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur. J. Cancer 46(7), 1260-1270 (2010). Established Met signaling as an important mediator in osteosarcoma.
47. Liao AT, McCleese J, Kamerling S, Christensen J, London CA. A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet. Comp. Oncol. 5(3), 177-196 (2007).
48. McCleese JK, Bear MD, Fossey SL et al. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer 125(12), 2792-2801 (2009).
49. Regenbrecht CR, Lehrach H, Adjaye J. Stemming cancer: Functional genomics of cancer stem cells in solid tumors. Stem. Cell Rev. 4(4), 319-328 (2008).
50. Gibbs CP, Kukekov VG, Reith JD et al. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 7(11), 967-976 (2005).
51. Wang L, Park P, Zhang H, La Marca F, Lin C-Y. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int. J. Cancer 128(2), 294-303 (2010).
52. Tirino V, Desiderio V, d'Aquino R et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3(10), e3469 (2008).
53. Levings PP, McGarry SV, Currie TP et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 69(14), 5648-5655 (2009). Verified a tumor-initiating cell population in osteosarcoma.
54. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432(7015), 396-401 (2004).
55. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123), 111-115 (2007).
56. Honoki K, Fujii H, Kubo A et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol. Rep. 24(2), 501-505 (2010).
57. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10(1), 55-63 (2004).
58. Dravid G, Ye Z, Hammond H et al. Defining the role of Wnt/b-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells 23(10), 1489-1501 (2005).
59. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res. 16(12), 3153-3162 (2010).
60. Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: Chemoprevention by diclofenac. Tumour Biol. 31(6), 623-631 (2010).
61. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348(10), 891-899 (2003).
62. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 3(3), 166-174 (2002).
63. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348(10), 883-890 (2003).
64. Xia JJ, Pei LB, Zhuang JP et al. Celecoxib inhibits b-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J. Int. Med. Res. 38(4), 1294-1304 (2010).
65. Cui C, Zhang Y, Wang L, Liu H, Cui G. Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid. J. Pharm. Pharmacol 61(10), 1353-1358 (2009).
66. Shah S, Hecht A, Pestell R, Byers SW. Trans-repression of b-catenin activity by nuclear receptors. J. Biol. Chem. 278(48), 48137-48145 (2003).
67. Park CH, Chang JY, Hahm ER, Park S, Kim H-K, Yang CH. Quercetin, a potent inhibitor against b-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun. 328(1), 227-234 (2005).
68. Kim J, Zhang X, Rieger-Christ KM et al. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem. 281(16), 10865-10875 (2006).
69. Jaiswal AS, Marlow BP, Gupta N, Narayan S. b-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21(55), 8414-8427 (2002).
70. Roccaro AM, Leleu X, Sacco A et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin. Cancer Res. 14(6), 1849-1858 (2008).
71. Kakarala M, Brenner DE, Korkaya H et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat 122(3), 777-785 (2010). Demonstrates that cancer stem cells can be targeted through modulation of the Wnt pathway.
72. Lepourcelet M, Chen Y-NP, France DS et al. Small-molecule antagonists of the oncogenic Tcf/b-catenin protein complex. Cancer Cell 5(1), 91-102 (2004).
73. Trosset J-Y, Dalvit C, Knapp S et al. Inhibition of protein-protein interactions: The discovery of druglike b-catenin inhibitors by combining virtual and biophysical screening. Proteins 64(1), 60-67 (2006).
74. Chen Z, Venkatesan AM, Dehnhardt CM et al. 2,4-diamino-quinazolines as inhibitors of b-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. Bioorg Med. Chem. Lett. 19(17), 4980-4983 (2009).
75. Grandy D, Shan J, Zhang X et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 284(24), 16256-16263 (2009).
76. Shan J, Shi D-L, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44(47), 15495-15503 (2005).
77. Fujii N, You L, Xu Z et al. An antagonist of dishevelled protein-protein interaction suppresses b-catenin-dependent tumor cell growth. Cancer Res. 67(2), 573-579 (2007).
78. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of b-catenin/CREB-binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA 101(34), 12682-12687 (2004).
79. He B, You L, Uematsu K et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6(1), 7-14 (2004).
80. Brown AM. Canonical Wnt signaling: High-throughput RNAi widens the path. Genome Biol. 6(9), 231 (2005).